Marinus Pharmaceuticals MRNS Stock
Marinus Pharmaceuticals Price Chart
Marinus Pharmaceuticals MRNS Financial and Trading Overview
| Marinus Pharmaceuticals stock price | 1.41 USD |
| Previous Close | 10.02 USD |
| Open | 9.98 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 9.28 - 10.04 USD |
| 52 Week Range | 3.47 - 11.15 USD |
| Volume | 878.98K USD |
| Avg. Volume | 736.26K USD |
| Market Cap | 495.37M USD |
| Beta (5Y Monthly) | 1.152112 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.63 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.6 USD |
MRNS Valuation Measures
| Enterprise Value | 454.78M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.8582678 |
| PEG Ratio (5 yr expected) | -0.17 |
| Price/Sales (ttm) | 22.857622 |
| Price/Book (mrq) | 6.0049024 |
| Enterprise Value/Revenue | 20.985 |
| Enterprise Value/EBITDA | -3.605 |
Trading Information
Marinus Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.152112 |
| 52-Week Change | 124.77% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 11.15 USD |
| 52 Week Low | 3.47 USD |
| 50-Day Moving Average | 8.28 USD |
| 200-Day Moving Average | 6.4 USD |
MRNS Share Statistics
| Avg. Volume (3 month) | 736.26K USD |
| Avg. Daily Volume (10-Days) | 1.03M USD |
| Shares Outstanding | 50.55M |
| Float | 36.69M |
| Short Ratio | 1.81 |
| % Held by Insiders | 0.77% |
| % Held by Institutions | 83.76% |
| Shares Short | 1.53M |
| Short % of Float | 3.06% |
| Short % of Shares Outstanding | 3.02% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -162.35% |
| Operating Margin (ttm) | -595.42% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -43.87% |
| Return on Equity (ttm) | -56.076% |
Income Statement
| Revenue (ttm) | 21.67M USD |
| Revenue Per Share (ttm) | 0.51 USD |
| Quarterly Revenue Growth (yoy) | -26.80% |
| Gross Profit (ttm) | -55943000 USD |
| EBITDA | -126154000 USD |
| Net Income Avi to Common (ttm) | -35185000 USD |
| Diluted EPS (ttm) | -0.68 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 199.2M USD |
| Total Cash Per Share (mrq) | 3.94 USD |
| Total Debt (mrq) | 105.54M USD |
| Total Debt/Equity (mrq) | 124.04 USD |
| Current Ratio (mrq) | 10.226 |
| Book Value Per Share (mrq) | 1.632 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -126709000 USD |
| Levered Free Cash Flow (ttm) | -82011376 USD |
Profile of Marinus Pharmaceuticals
| Country | United States |
| State | PA |
| City | Radnor |
| Address | 5 Radnor Corporate Center |
| ZIP | 19087 |
| Phone | 484 801 4670 |
| Website | https://marinuspharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 151 |
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Q&A For Marinus Pharmaceuticals Stock
What is a current MRNS stock price?
Marinus Pharmaceuticals MRNS stock price today per share is 1.41 USD.
How to purchase Marinus Pharmaceuticals stock?
You can buy MRNS shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Marinus Pharmaceuticals?
The stock symbol or ticker of Marinus Pharmaceuticals is MRNS.
Which industry does the Marinus Pharmaceuticals company belong to?
The Marinus Pharmaceuticals industry is Biotechnology.
How many shares does Marinus Pharmaceuticals have in circulation?
The max supply of Marinus Pharmaceuticals shares is 292.97M.
What is Marinus Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Marinus Pharmaceuticals PE Ratio is now.
What was Marinus Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Marinus Pharmaceuticals EPS is -2.63 USD over the trailing 12 months.
Which sector does the Marinus Pharmaceuticals company belong to?
The Marinus Pharmaceuticals sector is Healthcare.
Marinus Pharmaceuticals MRNS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}